home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Cancer Drug Has Unexpected Mode Of Action

 
  June, 27 2007 8:50
your information resource in human molecular genetics
 
     
A particular type of cancer drug works in a previously unexpected way, suggests a Nature paper published online.

Topoisomerase inhibitors, such as topotecan, are a class of anti-cancer drugs that act on proteins that relax a form of built-up stress in DNA called supercoiling.

It's thought that they act by stabilizing a covalent complex between the topoisomerase enzyme and DNA, which then sets up a road-block to the DNA replication machinery triggering cell death.

Nynke H Dekker and colleagues look at single topoisomerase molecules 'in the act'. They find that the inhibitors don't just stabilize an intermediate but actually affect the ability of topoisomerase to relax DNA supercoiling, suggesting a new mechanism by which these drugs cause cytotoxicity.

Author contacts:

Nynke H Dekker (Delft University of Technology, Netherlands)
E-mail: n.h.dekker@tudelft.nl

Daniel A Koster (Delft University of Technology, Netherlands)
E-mail: d.a.koster@tudelft.nl

(C) Nature press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.